Drug Profile
EdX 17
Alternative Names: EdX-17Latest Information Update: 15 Sep 2023
Price :
$50
*
At a glance
- Originator EpimedX
- Class Antianaemics; Plant proteins
- Mechanism of Action Fetal haemoglobin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Sickle cell anaemia
Most Recent Events
- 15 Sep 2023 Discontinued - Preclinical for Sickle cell anaemia in USA (Parenteral)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Sickle-cell-anaemia in USA (Parenteral)
- 10 Aug 2016 Preclinical trials in Sickle cell anaemia in USA (Parenteral)